(Q44889686)

7 December 2017

title

Effect of single-dose rituximab on steroid-dependent minimal-change nephrotic syndrome in adults (English)

1 reference

7 December 2017

1 reference

1 reference

Takashi Takei

1

1 reference

7 December 2017

Mitsuyo Itabashi

2

1 reference

7 December 2017

Takahito Moriyama

3

1 reference

7 December 2017

Chiari Kojima

4

1 reference

7 December 2017

Syunji Shiohira

5

1 reference

7 December 2017

Ari Shimizu

6

1 reference

7 December 2017

Yuki Tsuruta

7

1 reference

7 December 2017

Ayami Ochi

8

1 reference

7 December 2017

Nobuyuki Amemiya

9

1 reference

7 December 2017

Toshio Mochizuki

10

1 reference

7 December 2017

Keiko Uchida

11

1 reference

7 December 2017

Ken Tsuchiya

12

1 reference

7 December 2017

Kosaku Nitta

13

1 reference

7 December 2017

language of work or name

English

0 references

publication date

13 December 2012

1 reference

Nephrology Dialysis Transplantation

7 December 2017

published in

1 reference

7 December 2017

volume

28

1 reference

7 December 2017

issue

5

1 reference

7 December 2017

page(s)

1225-1232

1 reference

The characteristics of relapse in adult-onset minimal-change nephrotic syndrome

7 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS515

Combined cyclosporine and prednisolone therapy in adult patients with the first relapse of minimal-change nephrotic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS515

Risk factors for cyclosporine-induced tubulointerstitial lesions in children with minimal change nephrotic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS515

Cyclosporine-A-induced nephrotoxicity in children with minimal-change nephrotic syndrome: long-term treatment up to 10 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS515

Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS515

Rituximab in refractory antineutrophil cytoplasmic antibody-associated vasculitis: what is the current evidence?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS515

CD20: a target antigen for immunotherapy of autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS515

Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS515

Exacerbation of ulcerative colitis after rituximab salvage therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS515

Nephrotic syndrome with pollen hypersensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS515

Rapid remission of steroid and mycophenolate mofetil (mmf)-resistant minimal change nephrotic syndrome after rituximab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS515

21 January 2018

Identifiers

DOI

10.1093/NDT/GFS515

1 reference

7 December 2017

1 reference